Conclusions
Ototoxicity is a known side effect of platinum-based chemotherapeutics. Eleven pharmacological and non-pharmacological strategies have been proposed to address this issue in the adult cancer population. This review summarizes the effectiveness of each intervention for the prevention and treatment of hearing loss associated with cisplatin. Current studies’ results are limited by their suboptimal methodological quality and underreporting of safety outcomes. High-quality randomized clinical trials are warranted to clarify the significance of these preliminary findings. Future research should ensure to include patients’ reported outcomes and overlooked otic symptoms like tinnitus and vertigo.